PNC Financial Services Group
GLUE icon

PNC Financial Services Group’s Monte Rosa Therapeutics GLUE Stock Holding History

PNC Financial Services Group’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1K Hold
457
– – ﹤0.01% 4037
2026
Q1 		$7.52K Hold
457
– – ﹤0.01% 4077
2025
Q4 		$7.17K Hold
457
– – ﹤0.01% 4090
2025
Q3 		$3.39K Buy
457
+340
+291% +$1.8K ﹤0.01% 4347
2025
Q2 		$528 Buy
117
+51
+77% +$227 ﹤0.01% 4679
2025
Q1 		$306 Buy
66
+38
+136% +$233 ﹤0.01% 4723
2024
Q4 		$194 Hold
28
– – ﹤0.01% 4654
2024
Q3 		$148 Hold
28
– – ﹤0.01% 4701
2024
Q2 		$105 Buy
+28
New +$143 ﹤0.01% 4714

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group's GLUE Position: Q2 2026 in Review

PNC Financial Services Group held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 457 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

PNC Financial Services Group first reported a position in GLUE in Q2 2024 and has held it in 9 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • PNC Financial Services Group held 457 shares of Monte Rosa Therapeutics worth $11.1K as of Q2 2026.
  • PNC Financial Services Group left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4037 holding.
  • PNC Financial Services Group first reported a position in Monte Rosa Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.